- Home
- RELY vs SRRK Comparison
RELY vs SRRK Comparison
Compare RELY & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELY
- SRRK
- Stock Information
- Founded
- RELY 2011
- SRRK 2012
- Country
- RELY United States
- SRRK United States
- Employees
- RELY N/A
- SRRK N/A
- Industry
- RELY Computer Software: Prepackaged Software
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RELY Technology
- SRRK Health Care
- Exchange
- RELY Nasdaq
- SRRK Nasdaq
- Market Cap
- RELY 4.5B
- SRRK 4.2B
- IPO Year
- RELY 2021
- SRRK 2018
- Fundamental
- Price
- RELY $23.14
- SRRK $44.88
- Analyst Decision
- RELY Buy
- SRRK Strong Buy
- Analyst Count
- RELY 8
- SRRK 7
- Target Price
- RELY $23.13
- SRRK $40.43
- AVG Volume (30 Days)
- RELY 1.3M
- SRRK 985.1K
- Earning Date
- RELY 02-19-2025
- SRRK 11-12-2024
- Dividend Yield
- RELY N/A
- SRRK N/A
- EPS Growth
- RELY N/A
- SRRK N/A
- EPS
- RELY N/A
- SRRK N/A
- Revenue
- RELY $1,176,826,000.00
- SRRK N/A
- Revenue This Year
- RELY $35.55
- SRRK N/A
- Revenue Next Year
- RELY $24.22
- SRRK N/A
- P/E Ratio
- RELY N/A
- SRRK N/A
- Revenue Growth
- RELY 35.18
- SRRK N/A
- 52 Week Low
- RELY $11.60
- SRRK $6.76
- 52 Week High
- RELY $23.60
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- RELY 62.12
- SRRK 58.65
- Support Level
- RELY $22.11
- SRRK $42.74
- Resistance Level
- RELY $23.51
- SRRK $45.15
- Average True Range (ATR)
- RELY 0.57
- SRRK 2.39
- MACD
- RELY -0.08
- SRRK -0.24
- Stochastic Oscillator
- RELY 75.20
- SRRK 83.13
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.